← Back to Search

Other

LEO 152020 tablet for Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by LEO Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Are you at least 18 years old?
Have you had atopic dermatitis for at least a year?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0 to week 16+3 days
Awards & highlights

Study Summary

This trial is testing a new tablet to see if it works to treat atopic dermatitis and what the side effects are when compared with a placebo tablet. There will be a 16-week treatment period during which participants will take the tablets and visit the clinic for tests and evaluations.

Eligible Conditions
  • Atopic Dermatitis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You must be 18 or older to participate.
Select...
You have had eczema for at least one year.
Select...
You have moderate to severe atopic dermatitis, as diagnosed by a doctor.
Select...
Is your eczema present on at least 5% of your body? To help you understand, imagine that the palm of your hand is about 1% of your body surface area. So, is your eczema covering an area that's about the size of 5 hands?
Select...
Have you used a cream containing corticosteroids to treat your skin condition in the last 6 months, but it did not help improve your condition?
Select...
You haven't already tried at least three different types of treatments (like pills or injections) for your AD.
Select...
Have you ever had an irregular heartbeat?
Select...
You are not currently involved in another study testing a new treatment.
Select...
You are not currently pregnant or nursing a baby.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0 to week 16+3 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0 to week 16+3 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in EASI from baseline to Week 16
Secondary outcome measures
Number of adverse events from baseline to Week 16+3 days per subject

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LEO 152020 tablet - Dose regimen 3Experimental Treatment1 Intervention
Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
Group II: LEO 152020 tablet - Dose regimen 2Experimental Treatment1 Intervention
Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
Group III: LEO 152020 tablet - Dose regimen 1Experimental Treatment1 Intervention
Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
Group IV: LEO 152020 placebo tabletPlacebo Group1 Intervention
Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).

Find a Location

Who is running the clinical trial?

LEO PharmaLead Sponsor
269 Previous Clinical Trials
188,418 Total Patients Enrolled
Medical ExpertStudy DirectorLEO Pharma
53 Previous Clinical Trials
9,856 Total Patients Enrolled
~63 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top